Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute. Docetaxel has previously been shown to be more effective than doxorubicin (an anthracycline) for treating patients with advanced breast cancer. Therefore, researchers wanted to test it in patients receiving chemotherapy after surgery.
